UnitedHealth Group Faces Texas Probe Ahead of Q3 Earnings

UnitedHealth Group (UNH) is facing a new regulatory challenge as Texas Attorney General Ken Paxton launched an investigation into the company's practices just ahead of its third-quarter earnings release. The probe focuses on allegations that UnitedHealth may have hindered patients from accessing necessary care, with the attorney general issuing Civil Investigative Demands as part of the inquiry.

The investigation adds another layer of complexity for UnitedHealth as it prepares to report its Q3 2026 results on October 13, 2026. The company has recently shown signs of recovery, with Q2 2026 revenue reaching USD 112.03 billion and adjusted EPS of USD 6.38, beating consensus estimates by USD 1.44 and USD 1.22 billion, respectively.

UnitedHealth had set its fiscal 2026 adjusted EPS guidance between USD 19.50 and USD 20.00, making the upcoming earnings report a critical test for the company. Analysts have given the stock a consensus Buy rating with an average target price of USD 481.72, which is 29.7 percent above its current trading price of USD 371.46 as of October 5, 2026.

The stock has been trading within a 52-week range of USD 255.97 to USD 461.62, and its market capitalization stands at USD 337.3 billion. The company will release its Q3 2026 financial results before the market opens on October 13, followed by a conference call at 8:00 a.m. ET.